An approach of combining CAR-NK cells targeting epithelial cell adhesion molecule (EpCAM) with tyrosine inhibitor, regorafenib was able to boost the efficacy of CAR-NK cells against colorectal cancer (131). This evidence concerns the gene EPCAM and colorectal cancer.